CG preps new, expanded bladder cancer plans with FDA after ph. 3 win

Graphic of a number of arrows missing the bullseye on a target except for one arrow
CG now plans to complete one FDA submission by the end of 2027’s first quarter and file another in NMIBC by the second. (Julia Lemba/Getty Images)

CG Oncology showed in a late-stage study that its immunotherapy cretostimogene reduced the risk of tumor recurrence in certain patients with non-muscle invasive bladder cancer (NMIBC) following surgery.

The phase 3 results, which the company called “unprecedented” and “unparalleled,” demonstrated a 68% reduction in the risk of recurrence over the course of 17 months with no new safety signals. Patients in the study were considered intermediate-risk with high-grade Ta NMIBC.

Cretostimogene is an immunotherapy based on an oncolytic virus that is injected directly into a patient’s bladder to target cancer cells. In the adjuvant setting, the procedure follows surgery to remove the tumor.

Results from the 367-patient study, named PIVOT-006, could expand CG’s addressable population alongside a previous late-stage study showing significant response rate in patients with high-risk NMIBC.

The company plans to expand its initial FDA submission that included patients with bladder cancer that contains carcinoma in situ with or without papillary tumors to also include patients with high-grade papillary-only disease. This represents the full range of patients with bladder cancer that is unresponsive to the standard-of-care treatment called Bacillus Calmette-Guérin, according to CG.

CG now plans to complete that expanded FDA submission by the end of 2027’s first quarter. Meanwhile, in intermediate high-grade Ta NIMBC, the company aims to tender a second application with the FDA in next year's second quarter. 

“Today’s results highlight our differentiated clinical approach, aimed at exploring cretostimogene across the broad NMIBC spectrum and build upon our robust body of clinical evidence including what we believe to be the best-in-disease safety and tolerability data reported,” CG chief medical officer Vijay Kasturi, M.D., said in a release. “The significant improvement in recurrence-free survival observed in PIVOT-006 across both high-grade and low-grade patients underscores the promise of cretostimogene as an important potential new treatment option following tumor resection.”

CG has been public since a $380 million outing in 2024, a bright point in time when IPOs were only beginning to recover from a yearlong slump. Now, with further late-stage data in hand and a path to regulatory approval, the company has likely bolstered confidence in that strong debut.